Macquarie Group LTD Mersana Therapeutics, Inc. Transaction History
Macquarie Group LTD
- $85.1 Billion
- Q2 2024
A detailed history of Macquarie Group LTD transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 150,000 shares of MRSN stock, worth $277,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150,000
Previous 150,000
-0.0%
Holding current value
$277,500
Previous $672,000
55.21%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding MRSN
# of Institutions
124Shares Held
114MCall Options Held
73.5KPut Options Held
46.4K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$35.8 Million1.38% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$21 Million2.5% of portfolio
-
Nextech Invest Ag9.53MShares$17.6 Million3.61% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$16 Million3.56% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$15.5 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $180M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...